Table 5 Antibody agents targeting PD-1/PD-L1 approved by FDA

From: Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

Name

Diseases

Developer

Keytruda

Melanoma, non-small cell lung cancer

Merck Sharp & Dohme

Opdivo

Melanoma, head and neck cancer

Bristol Myers Squibb

Tecentriq

Non-small cell lung cancer, bladder cancer

Roche

Bavencio

Merkel cell carcinoma

Merck and Pfizer

Imfinzi

Urothelial carcinoma

AstraZeneca

Back to article page